Navigation Links
New studies may explain fractures in some who take osteoporosis drugs
Date:11/14/2013

d microscopic examinations and found differences in bone remodeling dynamics that were influenced by inherited differences among the animals.

"Baboons are anatomically and physiologically very similar to humans, and these animals live a long time, so they develop many of the same age-related diseases that we do," Havill said. "This makes them a good model for age-related diseases such as osteoporosis. The results of this study suggest an explanation for why some women respond differently to the widely prescribed bisphosphonates."

"This supports the potential for a scenario in which certain individuals who are genetically predisposed to cortical microstructure that is less mechanically advantageous may experience disadvantageous responses to remodeling suppression, such as being at higher risk for atypical femoral fractures," Havill wrote in the study.


'/>"/>

Contact: Joseph Carey
jcarey@txbiomed.org
210-258-9437
Texas Biomedical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Immunity studies cross scientific and continental borders (video)
2. ARC Future Fellows awarded $2.2M for immune and inflammation studies
3. Generation length for mammals: An essential reference point for conservation studies
4. Population Council to present more than 40 studies at International Conference on Family Planning
5. Mouse studies reveal promising vitamin D-based treatment for MS
6. Sam Houston State studies DNA preservation in mass disasters
7. HB-EGF protects intestines from a variety of injuries, pair of studies suggests
8. Neutron studies of HIV inhibitors reveal new areas for improvement
9. Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies
10. Family studies suggest rare genetic mutations team up to cause schizophrenia
11. UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... the Electronic Nose, which has the potential to diagnose ... grant from Grand Challenges Canada and the Bill & ... testing of this ground-breaking technology. The ... able to detect TB immediately and non-invasively from the ...
... family of compounds that includes one of the most ... treatments. But the difficulty producing these complex molecules in ... family for further drug leads. Now, a group of ... step toward the goal of synthetically producing Taxol and ...
... name "Sleeping Beauty" has helped to unlock vital clues ... A study published today used the Sleeping Beauty transposon ... drive colorectal cancer, identifying many more than previously thought. ... human cancer, which provides strong evidence that they are ...
Cached Biology News:Creating an 'electronic nose' to sniff out tuberculosis from a patient's breath 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 3Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 4Researchers discover genes involved in colorectal cancer 2
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... , SHANGHAI, Nov. ... Drug Administration (SFDA) has approved the,investigational new drug application (IND) ... treat diabetes. This IND,approval allows Biolaxy to initiate its first ... is a disorder characteristic of high blood glucose and poor,metabolism. ...
... ... by laboratories participating in or generating DNA records for the National DNA Index System. ... Madison, WI USA (PRWEB) -- ... laboratories participating in, or generating DNA records for, the National DNA Index System (NDIS). NDIS ...
... HTL , TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: ... systems and instruments for the stem cell research and fertility clinic ... ended September 30, 2009. , , Q3 2009 ... compared with $1.43 million in Q3 2008, - ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10